New drug combo offers hope for kids with Tough-to-Treat cancers
NCT ID NCT06607692
First seen Apr 17, 2026 · Last updated Jun 18, 2026 · Updated 5 times
Summary
This study is for children and teens (ages 3 to 18) with certain solid tumors that have returned or not responded to standard treatment. The tumors must have a specific marker called SSTR. The study combines two drugs: Lutathera (a radioactive drug that targets SSTR) and Olaparib (a pill that may make cancer cells more sensitive to radiation). The goal is to find the safest dose and see if the combination can shrink tumors. About 25 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
HM Monteprincipe
RECRUITINGBoadilla del Monte, Madrid, 28660, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.